Symrise AG announced that it is in advanced discussions with potential buyers regarding the divestment of its terpenes business. The process is being conducted as a structured bidding procedure. Based on the offers received to date, the company will apply the international accounting standard IFRS 5. In this context, Symrise AG will record a non-cash impairment charge of approximately 145 million euros in the fourth quarter of 2025, which will negatively impact its EBIT.
In addition, Symrise AG's investment in Sweden-listed Swedencare AB is subject to a non-cash impairment. Preliminary calculations indicate that this adjustment will result in a material deviation from the company's expected financial results for 2025 compared to current capital market expectations and its published forecast. Symrise AG will record a non-cash impairment charge of 150 million euros related to this investment in the fourth quarter of 2025, which will negatively affect EBITDA.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.